NASDAQ:APTX - Aptinyx Stock Price, Forecast & News

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx Inc (NASDAQ:APTX) released its earnings results on Tuesday, November, 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.44). The business earned $0.94 million during the quarter, compared to analyst estimates of $0.91 million. Aptinyx had a negative net margin of 1,523.09% and a negative return on equity of 44.24%. View Aptinyx's Earnings History.

Aptinyx is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Aptinyx.

6 equities research analysts have issued 12 month price targets for Aptinyx's shares. Their forecasts range from $7.00 to $12.00. On average, they expect Aptinyx's share price to reach $10.33 in the next twelve months. This suggests a possible upside of 220.9% from the stock's current price. View Analyst Price Targets for Aptinyx.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.

News coverage about APTX stock has been trending very negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptinyx earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for Aptinyx.

Aptinyx saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 192,200 shares, an increase of 13.4% from the January 15th total of 169,500 shares. Based on an average daily volume of 240,200 shares, the short-interest ratio is currently 0.8 days. Currently, 0.9% of the shares of the company are sold short. View Aptinyx's Current Options Chain.

Some companies that are related to Aptinyx include Urogen Pharma (URGN), Emisphere Technologies (EMIS), Kura Oncology (KURA), ZIOPHARM Oncology (ZIOP), XBiotech (XBIT), Crinetics Pharmaceuticals (CRNX), MacroGenics (MGNX), Neoleukin Therapeutics (NLTX), AC Immune (ACIU), Morphic (MORF), Milestone Pharmaceuticals (MIST), Assembly Biosciences (ASMB), CytoDyn (CYDY), Sinovac Biotech (SVA) and Satsuma Pharmaceuticals (STSA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), ADMA Biologics (ADMA), Canopy Growth (CGC), Kadmon (KDMN), Inovio Pharmaceuticals (INO), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).

(APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Aptinyx's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Farallon Capital Management LLC (0.93%), Renaissance Technologies LLC (0.70%), Jacobs Levy Equity Management Inc. (0.43%), Oxford Asset Management LLP (0.40%), Marshall Wace LLP (0.33%) and Acadian Asset Management LLC (0.26%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View Institutional Ownership Trends for Aptinyx.

APTX stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Marshall Wace LLP, Oxford Asset Management LLP, Russell Investments Group Ltd., Alambic Investment Management L.P. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Aptinyx.

APTX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., DCF Advisers LLC, Spark Investment Management LLC and Acadian Asset Management LLC. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View Insider Buying and Selling for Aptinyx.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $3.22.

Aptinyx has a market capitalization of $141.20 million and generates $6.57 million in revenue each year. The company earns $-53,280,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. View Additional Information About Aptinyx.

The official website for Aptinyx is http://www.aptinyx.com/.

Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]